Swedish biotech company Axelar has announced the commencement of its AXL1717 investigator-sponsored Phase I/II study in patients with brain tumours in the US.
The study is designed to assess the investigational drug in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AXL1717 is an oral small molecule insulin-like growth factor 1 (IGF-1) receptor pathway inhibitor.
Since majority of tumour cells rely on the IGF-1 receptor signal pathway, the IGF-1 receptor inhibitor drugs could act as potential cancer therapeutics.
Axelar CEO Dr Carl Harald Janson said; “Preclinical data supports treatment with AXL1717 in patients with astrocytomas and we now look forward to follow this important clinical study, since treatment for astrocytomas remains very challenging and new advances are necessary to improve clinical outcome.”
The Rush University Medical Center in Chicago is conducting the Phase I/II study, which is supported by Voices Against Brain Cancer and Gateway for Cancer Research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAt present, Axelar is also conducting AXL1717 Phase II trials in patients with non-small cell lung cancer, while the tolerability profile of the investigational compound was established in a Phase I/II trial conducted in 49 patients.
